Melatonin
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Melatonin
Melatonin: Known uses and market status in Australia
Summary
The TxGNN deep-learning model (score ≥ 0.99) produced candidates for Melatonin. Every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (all traceable model candidates are known uses) |
| Known uses among model candidates | 1 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| insomnia (disease) | licence in another country; approved indication: circadin is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 14188R | Slenyto | Tablet 1 mg (modified release) | Valid |
Safety Considerations
- Drug Interactions (20 records; 17 from DDInter plus 3 receptor pharmacology records). Moderate-level interactions include:
- Warfarin
- Deferasirox
- Alpelisib
- Anagrelide
- Lorlatinib
- Olaparib
- Osimertinib
- Rucaparib
- Teriflunomide
- Vemurafenib
- Ifosfamide
Minor-level interactions include cimetidine, obeticholic acid, caffeine, osilodrostat, ethinylestradiol and diethylstilbestrol.
- Knowledge-graph contraindication signals (not label text): the knowledge graph links melatonin with liver failure, kidney disease, autoimmune disease (including systemic lupus erythematosus and psoriasis), anxiety and depressive-type disorders, schizophrenia, substance abuse/dependence and constipation, among others. These need verification against the TGA-approved Product Information.
Warnings and contraindications from the product label were not available. Please refer to the TGA-approved Product Information (PI) for full safety information.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.